Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795694 | 0.82 | NOTUM (0.75) | NOTUMPOLBGAAALDH1A1HPGD | |
| SCHEMBL24819014 | 0.81 | NOTUM (0.52) | NOTUMBRD4MAPK1 | |
| SCHEMBL10414600 | 0.79 | NOTUM (0.50) | NOTUMGAAALDH1A1KDM4ELMNA | |
| SCHEMBL10414602 | 0.79 | NOTUM (0.50) | NOTUMGAAALDH1A1KDM4ELMNA | |
| SCHEMBL3800731 | 0.79 | ALDH1A1 (0.54) | NOTUMPOLBGAAALDH1A1HPGD | |
| SCHEMBL6851980 | 0.79 | NOTUM (0.58) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL11232897 | 0.75 | NOTUM (0.74) | NOTUMPOLBGAAALDH1A1HPGD | |
| SCHEMBL21776860 | 0.74 | NOTUM (1.00) | NOTUMGAAALDH1A1HPGDMAPK1 | |
| SCHEMBL942003 | 0.74 | NOTUM (0.64) | NOTUMPOLBGAAALDH1A1HPGD | |
| SCHEMBL23451501 | 0.74 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410151-B2 | Aminomethyl benzene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-02 | — | — | US | disclosed |
| EP-2262782-B1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-03 | — | — | US | disclosed |
| EP-2262782-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109904-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | CD47, BRD4, BRD3 | NOTUM 4042/4885POLB 2001/4885GAA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.